For children aged 6–11 years, GINA recently added IL-5 antibody therapy as an option, joining omalizumab and dupilumab as step 5 biologics for the treatment of pediatric severe asthma (Venkatesan, 2023). The gene discussed is IL5; the disease is asthma.